Articles published by Annexon Biosciences

Annexon Biosciences to Present at the 42nd Annual J.P. Morgan Healthcare Conference
December 27, 2023
From Annexon Biosciences
Via GlobeNewswire
Tickers
ANNX

Annexon Announces Pricing of $125.0 Million Underwritten Public Offering of Common Stock
December 20, 2023
From Annexon Biosciences
Via GlobeNewswire
Tickers
ANNX


Annexon Reports Phase 1 Results for ANX1502, its Oral Small Molecule Inhibitor of the Classical Complement Pathway
December 20, 2023
From Annexon Biosciences
Via GlobeNewswire
Tickers
ANNX

Annexon Reports Inducement Grants to New Employees Under Nasdaq Listing Rule 5635(c)(4)
December 18, 2023
From Annexon Biosciences
Via GlobeNewswire
Tickers
ANNX

Annexon Biosciences to Participate in the 6th Annual Evercore ISI HealthCONx Conference
November 22, 2023
From Annexon Biosciences
Via GlobeNewswire
Tickers
ANNX

Annexon Reports Significant Progress with its Priority Programs and Third Quarter 2023 Financial Results
November 13, 2023
From Annexon Biosciences
Via GlobeNewswire
Tickers
ANNX

From Annexon Biosciences
Via GlobeNewswire
Tickers
ANNX

Annexon Receives PRIME Designation from the EMA for ANX007 for the Treatment of Geographic Atrophy
October 24, 2023
From Annexon Biosciences
Via GlobeNewswire
Tickers
ANNX

Annexon Reports Inducement Grants to New Employees Under Nasdaq Listing Rule 5635(c)(4)
October 18, 2023
From Annexon Biosciences
Via GlobeNewswire
Tickers
ANNX

Annexon Announces Clinical and Regulatory Progress for ANX005 Pivotal Program in Guillain-Barré Syndrome (GBS)
October 10, 2023
From Annexon Biosciences
Via GlobeNewswire
Tickers
ANNX

Annexon Biosciences to Participate in the 2023 Cantor Global Healthcare Conference
September 19, 2023
From Annexon Biosciences
Via GlobeNewswire
Tickers
ANNX

Annexon Reports Inducement Grant to New Employee Under Nasdaq Listing Rule 5635(c)(4)
September 18, 2023
From Annexon Biosciences
Via GlobeNewswire
Tickers
ANNX

Annexon Highlights Recent Pipeline and Business Progress and Reports Second Quarter 2023 Financial Results
August 07, 2023
From Annexon Biosciences
Via GlobeNewswire
Tickers
ANNX

Annexon Reports Inducement Grant to New Employee Under Nasdaq Listing Rule 5635(c)(4)
August 02, 2023
From Annexon Biosciences
Via GlobeNewswire
Tickers
ANNX



From Annexon Biosciences
Via GlobeNewswire
Tickers
ANNX


Annexon Reports Inducement Grants to New Employees Under Nasdaq Listing Rule 5635(c)(4)
May 16, 2023
From Annexon Biosciences
Via GlobeNewswire
Tickers
ANNX

Annexon Reports First Quarter 2023 Financial Results and Highlights Recent Pipeline Progress
May 08, 2023
From Annexon Biosciences
Via GlobeNewswire
Tickers
ANNX

Annexon Biosciences to Participate in the 22nd Annual Needham Virtual Healthcare Conference
April 11, 2023
From Annexon Biosciences
Via GlobeNewswire
Tickers
ANNX

Annexon Reports Fourth Quarter and Year-End 2022 Financial Results and Reiterates Anticipated Milestones
March 06, 2023
From Annexon Biosciences
Via GlobeNewswire
Tickers
ANNX

From Annexon Biosciences
Via GlobeNewswire
Tickers
ANNX

Annexon Reports Inducement Grants to New Employees Under Nasdaq Listing Rule 5635(c)(4)
February 16, 2023
From Annexon Biosciences
Via GlobeNewswire
Tickers
ANNX

Annexon Reports Inducement Grant to New Employee Under Nasdaq Listing Rule 5635(c)(4)
January 17, 2023
From Annexon Biosciences
Via GlobeNewswire
Tickers
ANNX



Annexon to Present at 41st Annual J.P. Morgan Healthcare Conference
January 04, 2023
From Annexon Biosciences
Via GlobeNewswire
Tickers
ANNX

Annexon Reports Inducement Grant to New Employee Under Nasdaq Listing Rule 5635(c)(4)
November 17, 2022
From Annexon Biosciences
Via GlobeNewswire
Tickers
ANNX
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.
Business Insurance is a singular, authoritative news and information source for executives focused upon risk management, risk transfer and risk financing.
Never miss important news. Subscribe to our newsletter.
Register for free